Schisandrin Protects against Norepinephrine-Induced Myocardial Hypertrophic Injury by Inhibiting the JAK2/STAT3 Signaling Pathway

Figure 3

(a) Fluorescence picture of mitochondrial membrane potential changes (scale bar: 25 μm). (b) Red fluorescence intensity/green fluorescence intensity ratio statistics. (c) Band diagram of β-actin, JAK2, STAT3, BAX, and Bcl-2 protein expression detected by WB. (d) Statistical comparison of the gray value of JAK2/β-actin, STAT3/β-actin, BAX/β-actin, and Bcl-2/β-actin proteins. (e) The statistical value of the ratio of JAK2/β-actin, STAT3/β-actin, BAX/β-actin, and Bcl-2/β-actin mRNA. Ld, low dose; Md, medium dose; Hd, high dose; a,  < 0.05 vs. the control group; b,  < 0.05 vs. the model group; c,  < 0.05 vs. the captopril group; d,  < 0.05 vs. the medium-dose schisandrin group; and e,  < 0.05 vs. the CCCP group.

(a)

(b)

(c)

(d)

(e)